Azenta (AZTA) Hisse Özeti
Azenta, Inc. Amerika Birleşik Devletleri, Çin, Birleşik Krallık, Avrupa'nın geri kalanı, Asya Pasifik ve uluslararası alanda yaşam bilimleri endüstrisi için biyolojik ve kimyasal bileşik numune keşif ve yönetim çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden AZTA için herhangi bir risk tespit edilmedi.
AZTA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Azenta, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$37.40 |
| 52 Haftanın En Yüksek Seviyesi | US$41.73 |
| 52 Haftanın En Düşük Seviyesi | US$15.93 |
| Beta | 1.38 |
| 1 Aylık Değişim | 37.70% |
| 3 Aylık Değişim | 85.33% |
| 1 Yıllık Değişim | 18.54% |
| 3 Yıllık Değişim | -31.59% |
| 5 Yıllık Değişim | -55.84% |
| Halka arzdan bu yana değişim | 274.00% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 18
AZTA: Higher Guidance And Buybacks Will Offset Future P/E Compression Risks
Analysts have raised the fair value estimate for Azenta from $20.00 to $33.00. They highlighted a recent increase in the Street price target to $35.00 as support for this higher assessment.Seeking Alpha • Aug 14
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue
Summary AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out. There is reason to suspect the rally could undergo a reversal, which is why I am neutral on AZTA with a hold rating. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • Aug 18
AZTA: Higher Guidance And Buybacks Will Offset Future P/E Compression Risks
Analysts have raised the fair value estimate for Azenta from $20.00 to $33.00. They highlighted a recent increase in the Street price target to $35.00 as support for this higher assessment.Seeking Alpha • Aug 14
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue
Summary AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out. There is reason to suspect the rally could undergo a reversal, which is why I am neutral on AZTA with a hold rating. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 04
AZTA: Index Additions And Refined Assumptions Will Support Gradual Sentiment Recovery
Analysts have raised their price target for Azenta from $26.20 to $27.80, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that they view as better reflecting the stock's risk and return profile. What’s in the News for Azenta Robotics and software automation business Brooks Automation, which previously housed the life sciences operations that were later renamed Azenta, is reported by Bloomberg to be considering an IPO, according to periodical coverage.
Anlatı Güncellemesi • Jul 21
AZTA: Portfolio Refocus And Index Additions Will Support Future Upside Potential
Analysts have reduced their price target for Azenta to $33 from $45. This change reflects updated assumptions for slightly higher discount rates, more moderate revenue growth, softer profit margins, and a lower projected future P/E multiple.Anlatı Güncellemesi • Jul 07
AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns
Analysts have reduced their price target for Azenta from $30 to $20, citing updated assumptions that include a slightly higher discount rate, more modest revenue growth expectations, a marginally revised profit margin outlook, and a lower future P/E estimate. What’s in the News for Azenta Azenta, Inc.Anlatı Güncellemesi • Jun 23
AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery
The latest Narrative Update on Azenta reflects a lower analyst price target, with recent Street research trimming estimates by $5 to $10 as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Azenta points to a more cautious stance on valuation, with reduced price targets reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.Anlatı Güncellemesi • Jun 09
AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery
Analysts have reduced their average price target on Azenta by $15, reflecting updated views on the stock's risk profile and earnings power. Analyst Commentary Recent Street research on Azenta has centered on lower price targets and a reassessment of the stock's risk and earnings outlook.Anlatı Güncellemesi • May 25
AZTA: 2026 Guidance And Calibrated Expectations Will Support Sentiment Recovery
Analysts have reduced their price targets on Azenta by $10 and $5 in recent research. The updated fair value estimate of $26.20 reflects more cautious assumptions on revenue growth and profit margins, even as the projected future P/E edges higher.Anlatı Güncellemesi • May 01
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.Anlatı Güncellemesi • Apr 15
AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery
Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.Anlatı Güncellemesi • Apr 01
AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery
Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.Anlatı Güncellemesi • Mar 18
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.Anlatı Güncellemesi • Mar 03
AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery
Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.Yeni Anlatı • Feb 25
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 17
AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.Yeni Anlatı • Feb 08
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 03
AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential
Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.Anlatı Güncellemesi • Jan 20
AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward
Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.Anlatı Güncellemesi • Jan 05
AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential
Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.Anlatı Güncellemesi • Dec 14
AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion
Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.Anlatı Güncellemesi • Nov 29
AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026
Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.Analiz Makalesi • Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye
Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...Anlatı Güncellemesi • Nov 14
AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.Anlatı Güncellemesi • Oct 30
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.Analiz Makalesi • Sep 12
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...Analiz Makalesi • Aug 07
Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...Analiz Makalesi • Jul 24
Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...Yeni Anlatı • May 28
Pharma And Biotech Outsourcing Will Shape Future Market Dynamics
Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.Seeking Alpha • Apr 17
Azenta: Life Science Business Failing To Come To Life
Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 05
Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...Analiz Makalesi • Mar 28
Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...Seeking Alpha • Jan 27
Azenta: Taking A Pass
Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 10
At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?
Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...Analiz Makalesi • Dec 20
A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...Analiz Makalesi • Nov 17
Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%
The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...Analiz Makalesi • Nov 14
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...Hissedar Getirileri
| AZTA | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 12.0% | 7.3% | -1.5% |
| 1Y | 18.5% | 25.1% | 17.9% |
Getiri vs. Endüstri: AZTA geçen yıl % 25.1 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: AZTA geçen yıl boyunca % 17.9 oranında getiri sağlayan US Piyasası ile eşleşti.
Fiyat Oynaklığı
| AZTA volatility | |
|---|---|
| AZTA Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: AZTA son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AZTA 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1978 | 2,900 | John P. Marotta | www.azenta.com |
Azenta, Inc. Amerika Birleşik Devletleri, Çin, Birleşik Krallık, Avrupa'nın geri kalanı, Asya Pasifik ve uluslararası alanda yaşam bilimleri endüstrisi için biyolojik ve kimyasal bileşik numune keşif ve yönetim çözümleri sunmaktadır. Örnek Yönetim Çözümleri ve Multiomics segmentleri aracılığıyla faaliyet göstermektedir. Numune Yönetimi Çözümleri segmenti, otomatik depolar, kriyojenik sistemler, otomatik numune tüpleri, sarf malzemeleri ve aletleri ve kontrollü hızda çözdürme cihazlarının yanı sıra numune deposu hizmetleri de dahil olmak üzere numune yönetimi ürünleri ve hizmetleri sunmaktadır.
Azenta, Inc. Temel Bilgiler Özeti
| AZTA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.60b |
| Kazançlar(TTM) | -US$112.09m |
| Gelir(TTM) | US$613.81m |
2.7x
P/S Oranı-14.6x
F/K OranıAZTA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AZTA gelir tablosu (TTM) | |
|---|---|
| Gelir | US$613.81m |
| Gelir Maliyeti | US$343.44m |
| Brüt Kâr | US$270.37m |
| Diğer Giderler | US$382.46m |
| Kazançlar | -US$112.09m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.56 |
| Brüt Marj | 44.05% |
| Net Kâr Marjı | -18.26% |
| Borç/Özkaynak Oranı | 0% |
AZTA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/21 11:56 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Azenta, Inc. 14 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Christopher Muse | Barclays |
| Brett Hodess | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |